Introduction:
The biosimilars market in Japan is experiencing significant growth, driven by the increasing demand for cost-effective alternatives to expensive biologic drugs. According to recent market research, the biosimilars market in Japan is projected to reach $X billion by 2026, with a CAGR of X%. This report will explore the top 20 leading biosimilars brands in Japan in 2026.
1. Nivestim (Hospira)
Nivestim, a biosimilar of Neupogen, has gained significant market share in Japan due to its lower cost and comparable efficacy in treating neutropenia. With a production volume of X units in 2026, Nivestim is one of the top biosimilar brands in the Japanese market.
2. Remsima (Celltrion)
Remsima, a biosimilar of Remicade, has captured a significant market share in Japan with its competitive pricing and high-quality standards. With exports to various countries, Remsima is a key player in the biosimilars market.
3. Flixabi (Biogen)
Flixabi, a biosimilar of Remicade, has gained popularity in Japan for its effectiveness in treating inflammatory diseases. With a market share of X%, Flixabi is a leading biosimilar brand in the Japanese market.
4. Rituxan (Sandoz)
Rituxan, a biosimilar of Rituximab, has shown strong performance in the Japanese market with a production volume of X units in 2026. With its cost-effective pricing, Rituxan is a top choice for patients and healthcare providers.
5. Binocrit (Sandoz)
Binocrit, a biosimilar of Epogen, has established itself as a leading biosimilar brand in Japan with its high-quality standards and competitive pricing. With a market share of X%, Binocrit is a key player in the biosimilars market.
6. Zarxio (Sandoz)
Zarxio, a biosimilar of Neupogen, has gained traction in Japan for its cost-effective alternative to biologic drugs. With exports to various countries, Zarxio is a top biosimilar brand in the Japanese market.
7. Inflectra (Hospira)
Inflectra, a biosimilar of Remicade, has shown strong performance in Japan with a market share of X%. With its competitive pricing and efficacy, Inflectra is a top choice for patients and healthcare providers.
8. Erelzi (Sandoz)
Erelzi, a biosimilar of Enbrel, has gained popularity in Japan for its effectiveness in treating autoimmune diseases. With a production volume of X units in 2026, Erelzi is a leading biosimilar brand in the Japanese market.
9. Rixathon (Sandoz)
Rixathon, a biosimilar of MabThera, has captured a significant market share in Japan with its competitive pricing and high-quality standards. With exports to various countries, Rixathon is a key player in the biosimilars market.
10. Truxima (Celltrion)
Truxima, a biosimilar of Rituximab, has shown strong performance in the Japanese market with a market share of X%. With its cost-effective pricing, Truxima is a top choice for patients and healthcare providers.
11. Herzuma (Celltrion)
Herzuma, a biosimilar of Herceptin, has gained traction in Japan for its cost-effective alternative to biologic drugs. With a production volume of X units in 2026, Herzuma is a top biosimilar brand in the Japanese market.
12. Udenyca (Coherus Biosciences)
Udenyca, a biosimilar of Neulasta, has established itself as a leading biosimilar brand in Japan with its high-quality standards and competitive pricing. With a market share of X%, Udenyca is a key player in the biosimilars market.
13. Riximyo (Celltrion)
Riximyo, a biosimilar of MabThera, has gained popularity in Japan for its effectiveness in treating autoimmune diseases. With exports to various countries, Riximyo is a leading biosimilar brand in the Japanese market.
14. Ontruzant (Samsung Bioepis)
Ontruzant, a biosimilar of Herceptin, has captured a significant market share in Japan with its competitive pricing and high-quality standards. With a production volume of X units in 2026, Ontruzant is a top choice for patients and healthcare providers.
15. Renflexis (Samsung Bioepis)
Renflexis, a biosimilar of Remicade, has shown strong performance in the Japanese market with a market share of X%. With its cost-effective pricing, Renflexis is a top biosimilar brand in the Japanese market.
16. Hadlima (Samsung Bioepis)
Hadlima, a biosimilar of Humira, has gained traction in Japan for its cost-effective alternative to biologic drugs. With a market share of X%, Hadlima is a key player in the biosimilars market.
17. Flixabi (Biogen)
Flixabi, a biosimilar of Remicade, has established itself as a leading biosimilar brand in Japan with its high-quality standards and competitive pricing. With exports to various countries, Flixabi is a top choice for patients and healthcare providers.
18. Benepali (Samsung Bioepis)
Benepali, a biosimilar of Enbrel, has gained popularity in Japan for its effectiveness in treating autoimmune diseases. With a production volume of X units in 2026, Benepali is a leading biosimilar brand in the Japanese market.
19. Imraldi (Samsung Bioepis)
Imraldi, a biosimilar of Humira, has captured a significant market share in Japan with its competitive pricing and high-quality standards. With a market share of X%, Imraldi is a key player in the biosimilars market.
20. Truxima (Celltrion)
Truxima, a biosimilar of Rituximab, has shown strong performance in the Japanese market with a production volume of X units in 2026. With its cost-effective pricing, Truxima is a top choice for patients and healthcare providers.
Insights:
The biosimilars market in Japan is expected to continue its growth trajectory, driven by the increasing demand for cost-effective alternatives to biologic drugs. With a projected market size of $X billion by 2026, Japan remains a key market for biosimilar manufacturers. As more biosimilar brands enter the market, competition is expected to intensify, leading to further innovation and price competition. With favorable government policies supporting biosimilar adoption, the future looks promising for the biosimilars market in Japan.
Related Analysis: View Previous Industry Report
